Targets › PBPA
1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Jan 2027.
Open in Phaseline: the race on PBPA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Cephalexin Bacterial penicillin-binding protein inhibitor | PBPA | Phase 2 | Eczema | Jan 2027 |
Eczema (1)
small molecule (1)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.